Innovations in Precision and Regenerative Medicine - Drug Discovery TOE

Share this:
Published: 13 May 2016

This edition of the Drug Discovery TOE depicts innovations in precision and regenerative medicine. The most innovative achievements are presented, along with the profile of several game changers working in the field. The patent scenario is also illustrated, as well as, the industry interactions. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Protein delivery disrupting platform, synbioeconomy, enzyme discovery, Big Data, precision medicine, personalized medicine, regenerative medicine, cell encapsulation matrix, stem cells, veterinary medicine, bioinformatics, human cell line, oncology


Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..